Novo Nordisk

M&A

Novo Nordisk’s $10 Billion Bid Ups the Ante in Bidding War for Obesity Biotech Metsera

Photo via Mads Claus Rasmussen/ZUMAPRESS/Newscom

Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer’s bid of $8 billion.

2 min read

Photo by Douglas Cliff via iStock

Healthcare

Eli Lilly’s Sterling Results Highlight Rival Novo Nordisk’s Fading Fortunes

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

2 min read
Photo via Ritzau Scanpix/Sipa USA/Newscom

Healthcare

Novo Nordisk Seeks to Expand Liver Disease Treatments in $5.2B Deal for Bay Area Biotech

The acquisition comes as new CEO Mike Doustdar tries to revive once meteoric growth that has come crashing down to earth this year.

2 min read
Photo via James Black/Icon Sportswire DHN/James Black/Icon Sportswire/Newscom

Healthcare

Eli Lilly Upstages Novo Nordisk in Obesity Pill Face-Off

Both companies have been desperate to innovate beyond their current injectable GLP-1 weight-loss drugs for a while now.

1 min read

Healthcare

Lung Disease Breakthrough Boosts United Therapeutics — and its Rivals

Photo by Robina Weermeijer via Unsplash

About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.

2 min read

Healthcare

Novo Nordisk Backs Away From Hims & Hers Partnership

Photo via Abaca Press/Blondet Eliot/Abaca/Sipa USA/Newscom

Novo and Hims’ April team-up turned the two firms from competitors into collaborators at just the right moment.

2 min read

Healthcare

Hims & Hers Struggles After the FDA Puts a Ticking Clock on its Weight-Loss Drug

Photo by Chemist4U via CC BY-SA 2.0

Now that semaglutide’s no longer in shortage territory, the FDA said drug-makers have 90 days to wrap up production of their Novo knockoffs.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.